Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on Moxifloxacin for Treating Uncomplicated Acute Appendicitis in Adults

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of uncomplicated acute appendicitis, a condition where the appendix becomes inflamed but has not yet burst or caused severe complications. The study aims to determine if antibiotics can be omitted in treating this condition. Participants will receive either an oral antibiotic called moxifloxacin or a placebo. Moxifloxacin is a type of antibiotic that is commonly used to treat bacterial infections.

The purpose of the study is to compare the effectiveness of the antibiotic treatment with a placebo in managing uncomplicated acute appendicitis. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving to ensure unbiased results. The study will monitor the participants over a period of 30 days to see if the appendicitis resolves without the need for surgery, known as an appendectomy.

Throughout the study, researchers will also observe any complications that may arise after the treatment, the length of hospital stays, and any readmissions to the hospital. Additionally, they will assess the participants' pain levels, quality of life, and any costs associated with the treatment. The study will help determine if antibiotics are necessary for treating uncomplicated acute appendicitis or if they can be safely omitted.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after signing an informed consent form, confirming understanding and agreement to participate in the study.

    Eligibility is determined by age (18-60 years) and a CT scan confirming uncomplicated acute appendicitis.

  2. Step 2

    Randomization and treatment allocation

    Participants are randomly assigned to receive either the antibiotic treatment or a placebo.

    The antibiotic treatment consists of a 400 mg tablet of moxifloxacin, taken orally. The tablet is encapsulated to maintain blinding.

  3. Step 3

    Treatment administration

    The assigned treatment (either moxifloxacin or placebo) is administered once daily.

    The duration of the treatment is determined by the study protocol and monitored by the research team.

  4. Step 4

    Monitoring and follow-up

    Participants are monitored for 30 days to assess the resolution of acute appendicitis without the need for surgery.

    Regular follow-up visits are scheduled to evaluate health status, pain levels, and any complications.

  5. Step 5

    Evaluation of outcomes

    The primary outcome is the success of the treatment within 30 days, defined as discharge from the hospital without surgery.

    Secondary outcomes include any complications, recurrence of appendicitis, hospital stay duration, and quality of life assessments.

Who can join the trial?

3 criteria

  • The patient must provide a signed informed consent, which means they agree to participate in the study after understanding what it involves.
  • The patient must be between the ages of 18 and 60 years old.
  • The patient must have a diagnosis of uncomplicated acute appendicitis confirmed by a CT scan. A CT scan is a special type of X-ray that gives detailed pictures of the inside of the body.

Who cannot join the trial?

3 criteria

  • Patients with a different type of appendicitis that is not uncomplicated acute appendicitis cannot participate. This means if the appendicitis is more severe or has complications, they are not eligible.
  • Patients who are younger than 3 years old cannot participate.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Oral Antibiotic Therapy is being tested in this clinical trial to see if it can effectively treat uncomplicated acute appendicitis without the need for surgery. The goal is to determine if antibiotics alone can be a safe and effective treatment option for patients with this condition.

What is already known about the treatment

Amoxicillin – This medication is administered orally in the form of tablets or capsules. It is currently being studied in clinical trials for its effectiveness in treating uncomplicated acute appendicitis. Amoxicillin is commonly used to treat bacterial infections by inhibiting the synthesis of bacterial cell walls, leading to the destruction of the bacteria. It belongs to the class of antibiotics known as penicillins.

Investigated diseases

Uncomplicated Acute Appendicitis – This condition involves inflammation of the appendix, a small pouch attached to the large intestine. It is termed "uncomplicated" when the inflammation has not led to rupture or abscess formation. Symptoms typically include sudden pain that begins around the navel and shifts to the lower right abdomen, along with nausea, vomiting, and fever. The pain often worsens with movement, coughing, or sneezing. If untreated, the inflammation can progress, but in uncomplicated cases, it remains localized. The condition is usually diagnosed based on clinical symptoms and may require further observation to ensure it does not become complicated.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506213-21-00Protocol codeAPPAC IVEstimated enrolment498 patientsSponsorTurku University Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).